Physician profile
Anthony Shallin
NPI 1891734968
$1,716.67
in general payments reported to CMS, 2019-2025
25 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $184 · 2021: $206 · 2022: $65.51 · 2023: $274 · 2024: $246 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $327.95 | 2021-2025 | |
| Lilly USA, LLC | $154.16 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $153.42 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $136.83 | 2023-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $123.51 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $94.48 | 2019-2024 | Farxiga, Lynparza |
| Allergan, INC. | $73.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.17 | 2021-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $62.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.62 | 2019-2022 | |
| Ge Healthcare | $47.14 | 2025 | |
| Mylan Specialty L.P. | $46.14 | 2023 | Yupelri |
| Sanofi Pasteur INC. | $45.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $36.25 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.68 | 2020 | |
| Abbott Laboratories | $34.02 | 2019-2024 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $24.80 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $23.12 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $22.51 | 2025 | |
| Boston Scientific Corporation | $21.19 | 2019 | |
| Nevro Corp. | $17.63 | 2023 | Senza |
| Abbvie INC. | $15.16 | 2021 | |
| Modernatx, INC. | $14.14 | 2024 | Moderna Covid-19 Vaccine |
| Ibsa Pharma INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Shallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.